Paragon 28
About: Paragon 28 Inc is a medical devices company that develops, distributes, and sells medical devices in the foot and ankle segment of the orthopedic implant marketplace. Its products include plates and plating systems, screws, staples, and nails aimed to address all major foot and ankle procedures including ankle, Charcot, fracture fixation, hallux valgus, hammertoe, and flat foot. The company's suite of surgical solutions comprises nearly 80 product systems to help fit the specific needs of each patient and procedure. Geographically the company generates the majority of its revenue from the United States.
Employees: 574
0
Funds holding %
of 7,139 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
869% more call options, than puts
Call options by funds: $126K | Put options by funds: $13K
100% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 15
44% more capital invested
Capital invested by funds: $340M [Q3] → $491M (+$150M) [Q4]
13% more funds holding
Funds holding: 112 [Q3] → 127 (+15) [Q4]
0% more funds holding in top 10
Funds holding in top 10: 5 [Q3] → 5 (+0) [Q4]
5% less repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 40
5.43% less ownership
Funds ownership: 62.2% [Q3] → 56.77% (-5.43%) [Q4]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$13
0%
upside
Avg. target
$13
0%
upside
High target
$13
0%
upside
2 analyst ratings
0 positive
0%
2 neutral
100%
0 negative
0%
Stephens & Co. Mason Carrico 40% 1-year accuracy 8 / 20 met price target | 0%downside $13 | Equal-Weight Downgraded | 30 Jan 2025 |
Needham Mike Matson 55% 1-year accuracy 67 / 122 met price target | 0%downside $13 | Hold Downgraded | 29 Jan 2025 |
Financial journalist opinion
Based on 23 articles about FNA published over the past 30 days
Neutral
Accesswire
1 week ago
Bronstein, Gewirtz & Grossman, LLC Is Investigating Paragon 28, Inc. (FNA) And Encourages Shareholders to Connect
NEW YORK CITY, NY / ACCESS Newswire / February 14, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Paragon 28, Inc. ("Paragon 28" or "the Company") (NYSE:FNA). Investors who purchased Paragon 28 securities prior to May 5, 2023, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/FNA.
Neutral
Accesswire
1 week ago
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates FNA and TGI on Behalf of Shareholders
NEW YORK, NY / ACCESS Newswire / February 13, 2025 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Paragon 28, Inc. (NYSE:FNA)'s sale to Zimmer Biomet Holdings, Inc. for $13.00 per share in cash. Paragon 28 shareholders will also receive a non-tradeable contingent value right entitling the holder to receive up to $1.00 per share in cash if certain revenue milestones are achieved.
Neutral
Accesswire
1 week ago
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Paragon 28, Inc. (FNA) And Encourages Shareholders to Reach Out
NEW YORK CITY, NY / ACCESS Newswire / February 13, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Paragon 28, Inc. ("Paragon 28" or "the Company") (NYSE:FNA). Investors who purchased Paragon 28 securities prior to May 5, 2023, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/FNA.
Neutral
Accesswire
1 week ago
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Paragon 28, Inc. (FNA) and Encourages Shareholders to Learn More About the Investigation
NEW YORK CITY, NY / ACCESS Newswire / February 12, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Paragon 28, Inc. ("Paragon 28" or "the Company") (NYSE:FNA). Investors who purchased Paragon 28 securities prior to May 5, 2023, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/FNA.
Neutral
Accesswire
1 week ago
Paragon 28, Inc. (FNA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation
NEW YORK CITY, NY / ACCESS Newswire / February 11, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Paragon 28, Inc. ("Paragon 28" or "the Company") (NYSE:FNA). Investors who purchased Paragon 28 securities prior to May 5, 2023, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/FNA.
Neutral
Accesswire
1 week ago
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Paragon 28, Inc. (FNA) and Encourages Investors to Learn More About the Investigation
NEW YORK CITY, NY / ACCESS Newswire / February 10, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Paragon 28, Inc. ("Paragon 28" or "the Company") (NYSE:FNA). Investors who purchased Paragon 28 securities prior to May 5, 2023, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/FNA.
Neutral
Accesswire
1 week ago
Paragon 28, Inc. (FNA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
NEW YORK CITY, NY / ACCESS Newswire / February 9, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Paragon 28, Inc. ("Paragon 28" or "the Company") (NYSE:FNA). Investors who purchased Paragon 28 securities prior to May 5, 2023, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/FNA.
Neutral
Accesswire
2 weeks ago
Bronstein, Gewirtz & Grossman, LLC Is Investigating Paragon 28, Inc. (FNA) And Encourages Investors to Connect
NEW YORK CITY, NY / ACCESS Newswire / February 7, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Paragon 28, Inc. ("Paragon 28" or "the Company") (NYSE:FNA). Investors who purchased Paragon 28 securities prior to May 5, 2023, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/FNA.
Neutral
Accesswire
2 weeks ago
Bronstein, Gewirtz & Grossman, LLC Encourages Paragon 28, Inc. (FNA) Stockholders to Inquire about Securities Investigation
NEW YORK CITY, NY / ACCESS Newswire / February 6, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Paragon 28, Inc. ("Paragon 28" or "the Company") (NYSE:FNA). Investors who purchased Paragon 28 securities prior to May 5, 2023, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/FNA.
Neutral
PRNewsWire
2 weeks ago
Zimmer Biomet Announces Fourth Quarter and Full-Year 2024 Financial Results
Fourth quarter net sales of $2.023 billion increased 4.3% and 4.9% on a constant currency1 basis Fourth quarter diluted earnings per share were $1.20; adjusted1 diluted earnings per share were $2.31 Full-year net sales of $7.679 billion increased 3.8% and 4.8% on a constant currency1 basis Full-year diluted earnings per share were $4.43; adjusted1 diluted earnings per share were $8.00 Company provides full-year 2025 financial guidance WARSAW, Ind. , Feb. 6, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today reported financial results for the quarter and year ended December 31, 2024.
Charts implemented using Lightweight Charts™